News Detail
Indianapolis, 8 Nov 2023: In the Big Pharma battle to treat obesity, Novo Nordisk sprinted to an early lead, but Eli Lilly is catching up quickly.
Wednesday, the Indianapolis-based company View Details
Source : Fierce Pharma
Eli Lilly
weight loss
Obesity
GLP-1
tirzepatide
FDA approval
Fierce Pharma Homepage
Pharma
Related News
- Innovative Cancer Treatment may sometimes cause Cancer, US FDA. Says (01-12-2023)
- New NMC logo facing the wrath of Medical fraternity (01-12-2023)
- MP: Local pharma firms record an upside in overseas orders (01-12-2023)
- Karnataka’s draft biotech policy draws up efforts to chalk out transformative growth trajectory (01-12-2023)
- India so far approved 15 vaccines and five booster doses: CDSCO (01-12-2023)
- US FDA flags data manipulation, management failures in warning letter to Intas on import alert (01-12-2023)
- PCI to Pharmacy Council of India to launch revamped "DIGI-PHARMed" application today (01-12-2023)
- Ahmedabad Crime Branch arrested two people with banned tabs, intoxicating syrup (01-12-2023)
- How Patanjali rode on the shoulders of Big Media (30-11-2023)
- 5 Dead, 2 Hospitalized after Consuming Ayurvedic 'Kalmeghasav' in Gujarat (30-11-2023)